1989
DOI: 10.1001/archneur.1989.00520440064022
|View full text |Cite
|
Sign up to set email alerts
|

Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

2
86
0

Year Published

1991
1991
2000
2000

Publication Types

Select...
9

Relationship

1
8

Authors

Journals

citations
Cited by 530 publications
(89 citation statements)
references
References 28 publications
2
86
0
Order By: Relevance
“…12,23,32 Although differences in opinion still exist, 6,31,38 MMN is generally regarded as a distinct entity because it represents a relatively uniform group of patients who differ significantly from CIDP patients with respect to laboratory features, histopathology, and response to treatment. 5 An argument can be made that MADSAM neuropathy is simply an asymmetrical presentation of CIDP. MADSAM neuropathy and CIDP are similar with respect to CSF and sensory nerve biopsy findings as well as response to corticosteroids.…”
Section: Discussionmentioning
confidence: 99%
“…12,23,32 Although differences in opinion still exist, 6,31,38 MMN is generally regarded as a distinct entity because it represents a relatively uniform group of patients who differ significantly from CIDP patients with respect to laboratory features, histopathology, and response to treatment. 5 An argument can be made that MADSAM neuropathy is simply an asymmetrical presentation of CIDP. MADSAM neuropathy and CIDP are similar with respect to CSF and sensory nerve biopsy findings as well as response to corticosteroids.…”
Section: Discussionmentioning
confidence: 99%
“…Approximately 95% of patients with CIDP initially respond to prednisone, but dose reduction frequently results in a relapse. 4 Plasma exchange is helpful in patients whose condition is deteriorating rapidly, in nonresponders to prednisone, and in patients who need to avoid prednisone. The beneficial effect of plasma exchange begins to fade 10 to (table 3).…”
mentioning
confidence: 99%
“…In several large series of Caucasian patients, 1 to 10% recovered completely and had acute recurrences several months to decades later (1 (2,4). Progression of weakness ofCIDP typically lasts more than eight weeks, far slower than GBS, however, some "intermediate" cases whose peak of weakness is found between 1 to 2 months have sometimes been reported (14).…”
Section: Discussionmentioning
confidence: 99%
“…In Japan, there is no detailed analysis of recurrent GBS as it has rarely been reported in the Japanese literature. Recognition of recurrent GBS is important, because relapse is common in another group of idiopathic acquired neuropathies, chronic inflammatory demyelinating polyneuropathy (CIDP) (2). Here we describe 3 of our cases, who were among 76 patients with GBS; we further summarize the clinical features of 1 1 patients with recurrent GBS reported in the Japanese literature.…”
Section: Introductionmentioning
confidence: 89%